Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study
Background. Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient–provider discussions, improve treatment development, and inform HC...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | MDM Policy & Practice |
| Online Access: | https://doi.org/10.1177/23814683251340055 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184517504991232 |
|---|---|
| author | Andrew M. Moon Daniel Richardson Gabriel V. Lupu Donna M. Evon Hanna K. Sanoff Jessica Carda-Auten Randall Teal Myra Waheed Ethan Basch David M. Mauro Ted K. Yanagihara David A. Gerber Neil D. Shah Oren K. Fix Hersh Shroff Tammy Triglianos Jonathan D. Sorah Jingquan Jia Ashwin Somasundaram Lynne I. Wagner Michael D. Kappelman Matthew Schooler Julia R. Phillips Hiwot A. Ekuban Ariel E. Sanderford A. Sidney Barritt |
| author_facet | Andrew M. Moon Daniel Richardson Gabriel V. Lupu Donna M. Evon Hanna K. Sanoff Jessica Carda-Auten Randall Teal Myra Waheed Ethan Basch David M. Mauro Ted K. Yanagihara David A. Gerber Neil D. Shah Oren K. Fix Hersh Shroff Tammy Triglianos Jonathan D. Sorah Jingquan Jia Ashwin Somasundaram Lynne I. Wagner Michael D. Kappelman Matthew Schooler Julia R. Phillips Hiwot A. Ekuban Ariel E. Sanderford A. Sidney Barritt |
| author_sort | Andrew M. Moon |
| collection | DOAJ |
| description | Background. Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient–provider discussions, improve treatment development, and inform HCC treatment guidelines. We performed a qualitative study involving patients with HCC and medical providers to assess the role of patient preferences in HCC treatment choices. Methods. Patient participants included those with HCC seen within a single tertiary care center. Provider participants involved physicians and advanced practice providers who cared for patients with HCC from a single center. Baseline and posttreatment patient interviews were conducted by trained qualitative research experts, informed by semi-structured interview guides, and analyzed using thematic analysis with pilot-tested codebooks. Summaries included a narrative description of the themes and subthemes that emerged related to each code, and illustrative quotes were used to highlight each theme. Results. The baseline interview involved 30 patients with HCC (22 of whom participated in follow-up interviews) and 10 providers who cared for patients with HCC. Patients identified factors considered when making treatment decisions included provider confidence and experience, patient prior cancer experiences, other health issues, and faith. Providers primarily discussed the role of Barcelona Clinic Liver Cancer stage, liver function, performance status, and eligibility of liver transplantation in making treatment recommendations. There was general agreement among providers that there is a need to better understand the role of patient values to improve care for HCC. Limitations. Qualitative interviews were limited to patients and providers from a single center. Conclusions. This qualitative study provided information on the variety of values considered by both patients and providers in HCC treatment decisions and the importance of considering tradeoffs of efficacy, toxicity, and inconvenience/costs. Highlights Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient–provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines. This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs. These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions. |
| format | Article |
| id | doaj-art-ce2734bc27f549ea9471a7fdcff2227b |
| institution | OA Journals |
| issn | 2381-4683 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | MDM Policy & Practice |
| spelling | doaj-art-ce2734bc27f549ea9471a7fdcff2227b2025-08-20T02:17:01ZengSAGE PublishingMDM Policy & Practice2381-46832025-05-011010.1177/23814683251340055Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative StudyAndrew M. MoonDaniel RichardsonGabriel V. LupuDonna M. EvonHanna K. SanoffJessica Carda-AutenRandall TealMyra WaheedEthan BaschDavid M. MauroTed K. YanagiharaDavid A. GerberNeil D. ShahOren K. FixHersh ShroffTammy TriglianosJonathan D. SorahJingquan JiaAshwin SomasundaramLynne I. WagnerMichael D. KappelmanMatthew SchoolerJulia R. PhillipsHiwot A. EkubanAriel E. SanderfordA. Sidney BarrittBackground. Hepatocellular carcinoma (HCC) treatment decisions are becoming increasingly complex as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient–provider discussions, improve treatment development, and inform HCC treatment guidelines. We performed a qualitative study involving patients with HCC and medical providers to assess the role of patient preferences in HCC treatment choices. Methods. Patient participants included those with HCC seen within a single tertiary care center. Provider participants involved physicians and advanced practice providers who cared for patients with HCC from a single center. Baseline and posttreatment patient interviews were conducted by trained qualitative research experts, informed by semi-structured interview guides, and analyzed using thematic analysis with pilot-tested codebooks. Summaries included a narrative description of the themes and subthemes that emerged related to each code, and illustrative quotes were used to highlight each theme. Results. The baseline interview involved 30 patients with HCC (22 of whom participated in follow-up interviews) and 10 providers who cared for patients with HCC. Patients identified factors considered when making treatment decisions included provider confidence and experience, patient prior cancer experiences, other health issues, and faith. Providers primarily discussed the role of Barcelona Clinic Liver Cancer stage, liver function, performance status, and eligibility of liver transplantation in making treatment recommendations. There was general agreement among providers that there is a need to better understand the role of patient values to improve care for HCC. Limitations. Qualitative interviews were limited to patients and providers from a single center. Conclusions. This qualitative study provided information on the variety of values considered by both patients and providers in HCC treatment decisions and the importance of considering tradeoffs of efficacy, toxicity, and inconvenience/costs. Highlights Hepatocellular carcinoma (HCC) treatment decisions are often complex and may become increasingly so as new treatment options emerge. Improved understanding of tradeoffs and patient preferences in treatment decisions will enhance patient–provider discussions, facilitate patient-centered trials to develop new treatments, and inform HCC treatment guidelines. This qualitative study of patients and providers provided information on the values considered in HCC treatment decisions and the importance of considering the tradeoffs of efficacy, toxicity, and inconvenience/costs. These insights can be used to develop preference elicitation tools, perform large-scale preference elicitation surveys, and systematically assess and incorporate patient preferences into treatment decisions.https://doi.org/10.1177/23814683251340055 |
| spellingShingle | Andrew M. Moon Daniel Richardson Gabriel V. Lupu Donna M. Evon Hanna K. Sanoff Jessica Carda-Auten Randall Teal Myra Waheed Ethan Basch David M. Mauro Ted K. Yanagihara David A. Gerber Neil D. Shah Oren K. Fix Hersh Shroff Tammy Triglianos Jonathan D. Sorah Jingquan Jia Ashwin Somasundaram Lynne I. Wagner Michael D. Kappelman Matthew Schooler Julia R. Phillips Hiwot A. Ekuban Ariel E. Sanderford A. Sidney Barritt Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study MDM Policy & Practice |
| title | Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study |
| title_full | Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study |
| title_fullStr | Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study |
| title_full_unstemmed | Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study |
| title_short | Exploring the Role of Patient Preferences in Hepatocellular Carcinoma Treatment Decisions: A Qualitative Study |
| title_sort | exploring the role of patient preferences in hepatocellular carcinoma treatment decisions a qualitative study |
| url | https://doi.org/10.1177/23814683251340055 |
| work_keys_str_mv | AT andrewmmoon exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT danielrichardson exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT gabrielvlupu exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT donnamevon exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT hannaksanoff exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT jessicacardaauten exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT randallteal exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT myrawaheed exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT ethanbasch exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT davidmmauro exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT tedkyanagihara exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT davidagerber exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT neildshah exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT orenkfix exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT hershshroff exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT tammytriglianos exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT jonathandsorah exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT jingquanjia exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT ashwinsomasundaram exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT lynneiwagner exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT michaeldkappelman exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT matthewschooler exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT juliarphillips exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT hiwotaekuban exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT arielesanderford exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy AT asidneybarritt exploringtheroleofpatientpreferencesinhepatocellularcarcinomatreatmentdecisionsaqualitativestudy |